Suppr超能文献

一种基于细胞的靶点结合分析方法,用于鉴定脑啡肽E3泛素连接酶配体及其在HDAC6降解剂中的应用。

A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.

作者信息

Yang Ka, Zhao Yu, Nie Xueqing, Wu Hao, Wang Bo, Almodovar-Rivera Chelsi M, Xie Haibo, Tang Weiping

机构信息

School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA.

School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA.

出版信息

Cell Chem Biol. 2020 Jul 16;27(7):866-876.e8. doi: 10.1016/j.chembiol.2020.04.008. Epub 2020 May 14.

Abstract

Proteolysis-targeting chimeras (PROTACs) is a paradigm shift for small-molecule drug discovery. However, limited E3 ubiquitin ligase ligands with cellular activity are available. In vitro binding assays involve the expression and purification of a large amount of proteins and they often yield ligands that are inactive in cell-based assays due to poor cell permeability, stability, and other reasons. Herein, we report the development of a practical and efficient cell-based target engagement assay to evaluate the binding affinity of a small library of cereblon ligands to its E3 ligase in cells. Selected cell-permeable E3 ligase ligands derived from this assay are then used to construct HDAC6 degraders with cellular protein degradation activity. Because the assay does not involve any genetic engineering, it is relatively easy to transfer from one cell type to a different one.

摘要

蛋白酶靶向嵌合体(PROTACs)是小分子药物发现领域的一次范式转变。然而,具有细胞活性的E3泛素连接酶配体数量有限。体外结合试验需要大量蛋白质的表达和纯化,而且由于细胞通透性差、稳定性不佳及其他原因,这些试验所产生的配体在基于细胞的试验中往往没有活性。在此,我们报告了一种实用且高效的基于细胞的靶点结合试验的开发,用于评估一小部分大脑神经酰胺配体文库与细胞中E3连接酶的结合亲和力。然后,从该试验中筛选出具有细胞通透性的E3连接酶配体,用于构建具有细胞内蛋白质降解活性的HDAC6降解剂。由于该试验不涉及任何基因工程,因此相对容易从一种细胞类型转移到另一种细胞类型。

相似文献

7
PROTAC-mediated crosstalk between E3 ligases.PROTAC 介导的 E3 连接酶串扰。
Chem Commun (Camb). 2019 Feb 5;55(12):1821-1824. doi: 10.1039/c8cc09541h.

引用本文的文献

3
PROTACs Targeting Epigenetic Proteins.靶向表观遗传蛋白的PROTACs
Acta Mater Med. 2023 Oct 26;2(4):409-429. doi: 10.15212/amm-2023-0039. Epub 2023 Dec 6.
5
Degraders in epigenetic therapy: PROTACs and beyond.表观遗传学治疗中的降解剂:PROTAC 及其他。
Theranostics. 2024 Jan 27;14(4):1464-1499. doi: 10.7150/thno.92526. eCollection 2024.
10
PROTAC chemical probes for histone deacetylase enzymes.用于组蛋白去乙酰化酶的PROTAC化学探针。
RSC Chem Biol. 2023 Jul 27;4(9):623-634. doi: 10.1039/d3cb00105a. eCollection 2023 Aug 30.

本文引用的文献

4
PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.蛋白酶靶向嵌合体(PROTACs)——过去、现在与未来。
Drug Discov Today Technol. 2019 Apr;31:15-27. doi: 10.1016/j.ddtec.2019.01.002. Epub 2019 Feb 13.
5
Development of selective small molecule MDM2 degraders based on nutlin.基于 nutlin 的选择性小分子 MDM2 降解剂的开发。
Eur J Med Chem. 2019 Aug 15;176:476-491. doi: 10.1016/j.ejmech.2019.05.046. Epub 2019 May 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验